(Yicai) Jan. 14 -- NeuroXess has started construction work on the Chinese brain-computer interface startup's "super factory", which is expected to go live in the second half of this year and allow the cutting-edge technology to move from the laboratory to mass production.

The new plant, which will cover an area of about 14,300 square meters in its first phase in southeastern Jiangxi province, will make the world's second and China's first fully implantable BCI, Shanghai-based NeuroXess announced yesterday. It aims to achieve stable delivery in the tens of thousands of units, it noted.

In addition, the factory will make other NeuroXess products, including high-throughput implantable flexible electrodes, high-frequency electroencephalographs, and implanting surgical robots, the company said, adding that it will also serve as a data center to help optimize algorithms and develop next-generation products through neural signal data collection, processing, and analysis.

NeuroXess also plans to include a one-stop rehabilitation training center that highly reproduces real-life and work scenes at the plant, which will help patients implanted with BCIs rebuild their life skills and return to society with dignity, it pointed out.

Established in 2021, NeuroXess has completed more than 50 BCI human implant surgeries with the assistance of medical institutions. It completed the implantation of China's first fully implantable BCI with a built-in battery late last year, becoming only the second company to achieve the feat after Elon Musk's Neuralink.

The BCI industry is ready to move towards large-scale applications thanks to the technology maturing. Musk announced recently that Neuralink would launch mass production of BCI devices this year.

Chinese companies are chasing Neuralink, with the Shanghai government issuing an action plan for the cultivation of the BCI industry on Jan. 10, aiming to achieve the clinical application of semi-invasive devices by next year and fully realize the clinical application of all types of BCI by 2030.

Editor: Martin Kadiev